Skip to main content

ResearchResearch summary

Probiotic safety: what a 2023 expert consensus says

An ISAPP consensus discusses probiotic safety by strain, product quality, use, and host; it reports no Candida outcomes or named-product risk estimates.

In this pathway

Current topic
Probiotic safety: what a 2023 expert consensus saysCurrent

Page trust and updates

First published
2026-10-08
Evidence as of
2026-10-08
Last updated
2026-10-08
Authorship
Candipedia Research
What changed
Published paired summary of the selected ISAPP expert consensus; it adds general safety context but no Candida evidence or named-product estimate.
Mogana Das Murtey and Patchamuthu Ramasamy, "Saccharomyces cerevisiae, SEM image", licensed under CC BY 3.0

Bottom line

This ISAPP expert-panel perspective discusses probiotic safety, but it reports no original patient outcomes, Candida-specific data, or safety estimate for a named product. Its recommendations are general research and product-quality context, not an individual treatment rule.

Why this source matters

The authors frame safety as depending on the strain, product quality and manufacturing, how a product is given, its intended use, and the host. They discuss strain identity, antimicrobial-resistance screening, product testing, monitoring in vulnerable populations, and better reporting of harms. This helps explain why one probiotic finding cannot establish safety for every product or person.

Study and population

This is a consensus perspective, not a study of recruited patients. ISAPP convened the panel at its 2022 annual meeting; the authors describe a half-day discussion but do not report the panel size. The paper discusses generally healthy consumers and clinical populations, including preterm infants, critically ill or debilitated patients, people with compromised barriers or indwelling catheters, and pregnant or lactating women.

What was assessed

No probiotic product was assigned, no comparator was used, and there was no uniform dose, route, strain, or follow-up. The authors combined evidence and expert discussion about product identity and quality, antimicrobial resistance, invasive infection, vulnerable populations, colonization, interactions, and adverse-event reporting.

Results

The consensus produced recommendations, not original participant-level estimates. It provides no cohort denominator, probiotic-user person-time, Candida treatment outcome, or named-product safety rate.

The figures below come from prior studies or reviews cited by the consensus. A cited review of invasive infections in children reported 49 cases from 1995–2021; most children meeting the sepsis definition were younger than 2 years and had a predisposing condition such as prematurity or an indwelling IV catheter. The review reported successful antimicrobial treatment in 94% of cases. It did not supply a denominator of probiotic users, so these cases cannot establish frequency.

A cited review of 100 probiotic studies in pregnancy found that 28 reported adverse events, 11 described events considered potentially related to treatment, and 72 did not report adverse events. No serious maternal or infant concern was reported in those studies. These are counts of studies reporting events, not participant-level rates; the consensus passage does not give arm-specific denominators or time points.

A cited Cochrane analysis pooling 4 trials in obese pregnant women reported pre-eclampsia in 31/472 probiotic recipients and 17/483 placebo recipients. The consensus characterized the evidence as not robust. These figures do not estimate risk for all probiotic products or users.

Applicability

The paper is useful for interpreting broad probiotic safety claims: safety depends on strain, product, intended use, administration, and host. It does not evaluate probiotics for Candida, vulvovaginal candidiasis, intestinal Candida, or broad symptoms, and it cannot classify a named product as safe or unsafe for an individual. Local safety routes remain the responsibility of current locale-specific authority sources.

Limitations

This was an expert consensus perspective without a reproducible systematic search, formal evidence grading, reported consensus vote, or uniform reanalysis of its cited sources. It combines heterogeneous trials, reviews, case reports, and mechanistic work. The cited data do not provide a reliable user denominator for invasive infection, and adverse-event reporting is incomplete. Several long-term safety questions remain unresolved. The authors also disclose extensive commercial ties, and ISAPP receives contributions from member companies; the paper says an academic volunteer board controls its positions.

Contribution to the evidence

Contextual safety contribution. The consensus supports a strain-, product-, use-, and host-specific way to think about safety, including product-quality and harm-reporting priorities. It does not provide Candida-specific findings, original cohort or trial estimates, or a product-level risk estimate, so it does not change Candida claim verdicts or individual safety actions.

Practical change

No practical change. The consensus adds general safety and reporting context but supplies no Candida evidence or named-product estimate. Candida efficacy claims and locale-specific care routes remain unchanged.

Funding and conflicts

ISAPP funded travel for panel members without industry affiliations. ISAPP receives equal contributions from member companies involved in probiotic or prebiotic development, assessment, or marketing; the paper says an all-academic volunteer board sets its activities and positions and that industry members do not control those positions. Authors disclosed extensive commercial consulting, speaking, legal, board, and employment ties; individual disclosures appear in the article. One author also provided a CDC disclaimer and contribution note.

Source

Read the corrected original publication (published 15 March 2023; the article states that its minor correction did not affect academic content).

Study type, population, and sample scale

Study type
ISAPP expert-panel consensus perspective, not a systematic review or clinical trial
Population
No enrolled participants; the perspective discusses probiotic use among generally healthy consumers and clinical populations, including vulnerable patients.
Sample scale
No cohort or trial sample; consensus-panel size not reported.
Read the original source

Results

  • The consensus itself reports no original patient cohort, trial outcome estimates, probiotic-user denominator, or Candida-specific data. The numerical findings below are reported from prior studies or reviews cited in the perspective, not newly collected consensus results.
  • A cited review of invasive infections in children reported 49 cases from 1995–2021. Most children meeting the sepsis definition were younger than 2 years and had a predisposing condition such as prematurity or an indwelling IV catheter; 94% were treated successfully with antimicrobial therapy. No exposed-user or person-time denominator was available, so frequency could not be estimated.
  • A cited review of 100 probiotic studies in pregnancy found that 28 reported adverse events; 11 described events considered potentially related to treatment, while 72 did not report adverse events. No serious maternal or infant concern was reported in those studies. These are study-reporting counts, not participant incidence rates; the passage gives no arm-specific denominators or time points.
  • A cited Cochrane analysis of 4 trials in obese pregnant women reported pre-eclampsia in 31/472 probiotic recipients and 17/483 placebo recipients. The consensus described this evidence as not robust; these counts are not a product-independent safety estimate.

Limitations

The paper is an expert-panel consensus perspective.
It reports no systematic search method, protocol, formal evidence grading, consensus vote, or reproducible study-selection process.
The authors assemble heterogeneous reviews, trials, case reports, and mechanistic findings.
The perspective does not reanalyze them uniformly or produce pooled estimates.
The cited invasive-infection reports and safety studies have incomplete or absent exposure denominators and adverse-event reporting.
The consensus cannot estimate incidence or individual product risk from these sources.
Some long-term, microbiome, drug-interaction, colonization, and antimicrobial-resistance questions remain unresolved.
The paper identifies research needs; its recommendations do not resolve those uncertainties or establish that ordinary consumer use causes harm.
The author group reports extensive commercial relationships, and ISAPP receives industry contributions.
The paper states that its academic volunteer board sets ISAPP positions and industry members do not control them; readers should consider the disclosed context when interpreting consensus recommendations.

Applies to

  • General interpretation of probiotic safety as dependent on the organism or strain, product quality, administration, intended use, and host.
  • Context on quality assurance, resistance screening, monitoring, and adverse-event reporting in research and product evaluation.

Does not apply to

  • Candida treatment efficacy, vulvovaginal candidiasis, intestinal Candida, or broad Candida-attributed symptoms.
  • The incidence or likelihood of harm from any named retail probiotic product, strain, dose, or route.
  • An individual safety decision or locale-specific care action for pregnancy, immunocompromise, critical illness, or another vulnerable state.

Contribution to the current conclusion

Contextual

The consensus provides general context on strain-, product-, use-, and host-specific safety, quality assurance, and adverse-event reporting. It is not Candida-specific, evaluates no named product, and supplies no product-level risk estimate or basis for changing local care routes.

Related evidence map

Practical change or no change

No practical change to Candida treatment claims, named-product safety estimates, or locale-specific care routes. The paper adds general consensus context about product and host factors, quality, and reporting, but contains no Candida-specific outcome data.

Funding and conflicts

Funding
ISAPP funded travel for non-industry-affiliated panel members and receives equal contributions from member companies involved in probiotic or prebiotic development, assessment, or marketing. The paper says an all-academic volunteer board sets ISAPP activities and positions and industry members do not control them.
Conflicts
Authors disclosed extensive consulting, speaking, legal, board, and employment relationships with probiotic, food, and pharmaceutical companies; see the original article for individual disclosures. One author's CDC disclaimer and contribution note are also reported.
Paper date
2023-03-15

Sources

View all 1 source